Alnylam Pharmaceuticals
ALNY
$147.89
Share price
-1.33%
Change (1 day)
-28.28%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Revenue for Alnylam Pharmaceuticals (ALNY)
Revenue in 2023 (TTM): $1.82 B
According to Alnylam Pharmaceuticals
's latest financial reports the company's current revenue (TTM
) is $2.00 B.
In 2022 the company made a revenue of $1.03 B an increase over the years 2021 revenue that were of $0.84 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alnylam Pharmaceuticals from 2004 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $1.82 B | 76.23% |
| 2022 | $1.03 B | 22.88% |
| 2021 | $0.84 B | 71.31% |
| 2020 | $0.49 B | 124.28% |
| 2019 | $0.21 B | 193.36% |
| 2018 | $74.9 M | -16.69% |
| 2017 | $89.91 M | 90.66% |
| 2016 | $47.15 M | 14.75% |
| 2015 | $41.09 M | -18.72% |
| 2014 | $50.56 M | 7.2% |
| 2013 | $47.16 M | -29.31% |
| 2012 | $66.72 M | -19.37% |
| 2011 | $82.75 M | -17.28% |
| 2010 | $0.10 B | -0.49% |
| 2009 | $0.10 B | 4.54% |
| 2008 | $96.16 M | 88.94% |
| 2007 | $50.89 M | 89% |
| 2006 | $26.93 M | 371.13% |
| 2005 | $5.71 M | 33.61% |
| 2004 | $4.27 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $49.92 B | 2,392.04% | 🇨🇭 Switzerland |
 Sanofi SNY | $50.51 B | 2,421.47% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | $13.10 B | 553.91% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | $1.40 B | -29.95% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | N/A | N/A | 🇺🇸 USA |
 OPKO Health
OPK | $0.86 B | -56.90% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $15.84 B | 690.98% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | $0.18 B | -90.93% | 🇺🇸 USA |